27742373|t|Scutellarin attenuates vasospasm through the Erk5 - KLF2 - eNOS pathway after subarachnoid hemorrhage in rats
27742373|a|Angiographic vasospasm, especially in the early phases (<72h) of subarachnoid hemorrhage (SAH), is one of the major complications after an aneurysm rupture and is often the cause of delayed neurological deterioration. Scutellarin (SCU), a flavonoid extracted from the traditional Chinese herb Erigeron breviscapus, has been widely accepted as an antioxidant, but the effect of SCU on vasospasm after SAH remains elusive. Endovascular perforation was conducted to induce SAH in Sprague-Dawley rats. Then, the underlying mechanism of the anti-vasospasm effect of SCU was investigated using a modified Garcia scale, India ink angiography, cross-sectional area analysis, immunohistochemistry staining and western blot. SCU (50Î¼M, 100mg/kg) alleviated angiographic vasospasm and improved neurological function 48h after SAH and enhanced the expression of endothelial nitric oxide synthase (eNOS) at the intima of cerebral arteries. In addition, SCU upregulated the expression of phosphorylated extracellular-regulated kinase 5 (p-Erk5) and Kruppel-like factor 2 (KLF2) at 48h after SAH. However, the effects of SCU were reversed by the Erk5 inhibitor XMD8-92. Our results indicate that SCU could attenuate vasospasm and neurological deficits via modulating the Erk5 - KLF2 - eNOS pathway after SAH, which may provide an experimental basis for the clinical use of SCU treatment in SAH patients.
27742373	0	11	Scutellarin	T109	C0141783
27742373	23	32	vasospasm	T046	C0085616
27742373	45	49	Erk5	T116,T126	C0380568
27742373	52	56	KLF2	T116,T123	C1451409
27742373	59	63	eNOS	T116,T126	C1565682
27742373	64	71	pathway	T044	C0037080
27742373	78	101	subarachnoid hemorrhage	T047	C0038525
27742373	105	109	rats	T015	C0034715
27742373	110	122	Angiographic	T060	C0007767
27742373	123	132	vasospasm	T046	C0085616
27742373	175	198	subarachnoid hemorrhage	T047	C0038525
27742373	200	203	SAH	T047	C0038525
27742373	249	265	aneurysm rupture	T047	C0162869
27742373	292	326	delayed neurological deterioration	T184	C1536136
27742373	328	339	Scutellarin	T109	C0141783
27742373	341	344	SCU	T109	C0141783
27742373	349	358	flavonoid	T109	C0596577
27742373	390	402	Chinese herb	T121	C1134558
27742373	403	423	Erigeron breviscapus	T002	C1493752
27742373	456	467	antioxidant	T121	C0003402
27742373	487	490	SCU	T109	C0141783
27742373	494	503	vasospasm	T046	C0085616
27742373	510	513	SAH	T047	C0038525
27742373	531	543	Endovascular	T029	C0524425
27742373	544	555	perforation	T033	C0549099
27742373	580	583	SAH	T047	C0038525
27742373	587	606	Sprague-Dawley rats	T015	C0034715
27742373	646	667	anti-vasospasm effect	T033	C0243095
27742373	671	674	SCU	T109	C0141783
27742373	723	744	India ink angiography	T060	C0007767
27742373	746	775	cross-sectional area analysis	T081	C0003745
27742373	777	806	immunohistochemistry staining	T060	C0021044
27742373	811	823	western blot	T059	C0949466
27742373	825	828	SCU	T109	C0141783
27742373	846	856	alleviated	T080	C0392756
27742373	857	869	angiographic	T060	C0007767
27742373	870	879	vasospasm	T046	C0085616
27742373	893	914	neurological function	T042	C0027767
27742373	925	928	SAH	T047	C0038525
27742373	960	993	endothelial nitric oxide synthase	T116,T126	C1565682
27742373	995	999	eNOS	T116,T126	C1565682
27742373	1008	1014	intima	T024	C1256463
27742373	1018	1035	cerebral arteries	T023	C0007770
27742373	1050	1053	SCU	T109	C0141783
27742373	1054	1065	upregulated	T044	C0041904
27742373	1084	1131	phosphorylated extracellular-regulated kinase 5	T116,T126	C0380568
27742373	1133	1139	p-Erk5	T116,T126	C0380568
27742373	1145	1166	Kruppel-like factor 2	T116,T123	C1451409
27742373	1168	1172	KLF2	T116,T123	C1451409
27742373	1187	1190	SAH	T047	C0038525
27742373	1216	1219	SCU	T109	C0141783
27742373	1256	1263	XMD8-92	T109,T121	C3252765
27742373	1291	1294	SCU	T109	C0141783
27742373	1311	1320	vasospasm	T046	C0085616
27742373	1325	1346	neurological deficits	T033	C0521654
27742373	1366	1370	Erk5	T116,T126	C0380568
27742373	1373	1377	KLF2	T116,T123	C1451409
27742373	1380	1384	eNOS	T116,T126	C1565682
27742373	1385	1392	pathway	T044	C0037080
27742373	1399	1402	SAH	T047	C0038525
27742373	1468	1471	SCU	T109	C0141783
27742373	1472	1481	treatment	T061	C0087111
27742373	1485	1488	SAH	T047	C0038525
27742373	1489	1497	patients	T101	C0030705